Topic
Pharmaceutical Industry
Everything Briefed has filed against Pharmaceutical Industry, most recent first.
20 stories
Coverage20 shown
Novo Nordisk raises guidance, investors punish it anywayNovo Nordisk lifted its full-year outlook off strong Wegovy and Ozempic sales and the stock fell regardless, showing how far expectations had drifted after two years of obesity-drug euphoria. The g…Goldman-backed Attovia raises $289m in US IPOAttovia's IPO pricing gives Goldman Sachs another biotech listing to point to as evidence the IPO window is reopening for clinical-stage companies, not just profitable tech.KKR and a $6.7bn radiopharma deal say private equity still wants healthcareKKR's $4.3bn purchase of Integer Holdings, a medical device components maker, lands the same week Lantheus Holdings agrees to be acquired for an initial $6.7bn, and together they confirm that healt…J&J's $5.5bn talc offer is a number chosen to make trials go awayJohnson & Johnson's offer caps out at $5.5 billion, well below the $8.9 billion bankruptcy-channelled settlement plan that federal judges rejected twice in 2023 and 2024. The company has now tried …Edwards Lifesciences narrows guidance despite growthStructural heart device sales grew, but a narrowed range rather than a raise suggests management sees more risk in the back half of the year than analysts had priced in.Novo Nordisk sues Eli Lilly over Ozempic marketing claimsNovo Nordisk is accusing Eli Lilly of running materially misleading adverts for its GLP-1 rivals at the exact moment both companies are locked in the most valuable pharmaceutical arms race of the d…Intuitive Surgical falls on ACA and GLP-1 headwindsWeight-loss drugs are starting to dent demand for bariatric and related surgical procedures, while ACA marketplace changes threaten the insured patient volumes Intuitive's robotic systems depend on…Anthropic goes after pharma revenue with Claude ScienceAnthropic is launching Claude Science as a dedicated product for pharmaceutical and research workflows, a direct attempt to convert scientific credibility into enterprise contracts rather than wait…Merck pays $11.3bn to get serious about life science toolsGermany's Merck KGaA is buying US biotech tools company Bio-Techne for $11.3 billion, a deal that cements its position in the high-margin life science reagents and instruments market rather than pu…SpaceX's $75bn IPO makes Musk the world's first trillionaire and hands him an acquisition war chestSpaceX opened on Nasdaq at $150 per share, roughly 11% above its IPO price, and closed day one near $161, generating approximately $75 billion in proceeds and pushing Musk's net worth past the tril…Elon Musk's Wall Street consolidation play is the business story hiding behind the headlinesThe emerging read on Musk's corporate strategy is not the personality spectacle but the financial architecture: using Tesla's balance sheet, xAI's compute narrative, and X's data assets as interlin…Apotex raises C$1.3bn in Canada's largest IPO since 2021The generic drugmaker priced at the top of its C$20-24 range and upsized the offering on strong demand, making it Canada's biggest listing in five years. SK Capital Partners, which acquired Apotex …McKesson unit prices $2.25bn loan ahead of IPOThe medical-surgical distributor secured leveraged financing following Apollo's $1.25 billion convertible investment at a $13 billion valuation.ZYN becomes Trump World's nicotine of choiceNicotine pouches have become fashionable across Trump's political orbit, including Health Secretary RFK Jr., as Philip Morris International's ZYN brand captures 76 percent of the US market. The FDA…CSL crashes to 8-year low as $60bn erasedAustralia's former healthcare darling hit A$125.78, down 49.91 percent over 12 months and wiping A$60 billion from its market cap after dismal half-year results triggered another confidence collaps…Sun Pharma's $12bn Organon bet doubles down on women's healthIndia's largest drugmaker is acquiring US-listed Organon for $14 per share, creating a $12.4 billion combined entity that positions Sun Pharma as a top-25 global pharmaceutical company. The all-cas…Seaport Therapeutics raises $255m for depression drugs that might workThe antidepressant maker priced its IPO at the top of the range, targeting a $912 million valuation for technology that promises oral bioavailability without the liver damage typical of neuropsychi…Novo-backed Avalyn raises $300m as biotech IPOs roar backAvalyn Pharma priced its IPO at the top of range and upsized to $300 million, making it one of 2026's largest biotech debuts. The inhaled lung disease specialist targets 100,000 US patients with re…Purdue Pharma to pay $8 billion to end US opioid casePurdue Pharma agreed to an $8 billion fine and guilty pleas to criminal conspiracy charges, while the Sackler family will pay $225 million in civil penalties to resolve opioid marketing allegations…Hungary reclaims oil and pharma assets from Orbán-linked academyHungary is seizing back oil and pharmaceutical company shares from a pro-Orbán academic foundation, marking a rare reversal of the prime minister's decade-long asset redistribution strategy. The mo…